Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Risk of second primary cancer in survivors of in situ melanoma.

Kimlin MG, Youlden DR, Brodie AM, DiSipio T, Youl P, Nair-Shalliker V, Baade PD.

J Invest Dermatol. 2018 Nov 10. pii: S0022-202X(18)32804-5. doi: 10.1016/j.jid.2018.11.001. [Epub ahead of print]

PMID:
30423330
2.

Investigating the patterns and determinants of seasonal variation in vitamin D status in Australian adults: the Seasonal D Cohort Study.

King L, Dear K, Harrison SL, van der Mei I, Brodie AM, Kimlin MG, Lucas RM.

BMC Public Health. 2016 Aug 26;16:892. doi: 10.1186/s12889-016-3582-z.

3.

Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.

Njar VC, Brodie AM.

J Med Chem. 2015 Mar 12;58(5):2077-87. doi: 10.1021/jm501239f. Epub 2015 Jan 28.

PMID:
25591066
4.

Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance.

Kesmodel SB, Sabnis GJ, Chumsri S, Brodie AM.

Curr Pharm Des. 2014;20(42):6575-83. Review.

PMID:
25341934
5.

The contributions of solar ultraviolet radiation exposure and other determinants to serum 25-hydroxyvitamin D concentrations in Australian adults: the AusD Study.

Kimlin MG, Lucas RM, Harrison SL, van der Mei I, Armstrong BK, Whiteman DC, Kricker A, Nowak M, Brodie AM, Sun J.

Am J Epidemiol. 2014 Apr 1;179(7):864-74. doi: 10.1093/aje/kwt446. Epub 2014 Feb 25.

PMID:
24573539
6.

Measuring exposure to solar ultraviolet radiation using a dosimetric technique: understanding participant compliance issues.

Sun J, Lucas RM, Harrison SL, van der Mei I, Whiteman DC, Mason R, Nowak M, Brodie AM, Kimlin MG.

Photochem Photobiol. 2014 Jul-Aug;90(4):919-24. doi: 10.1111/php.12265. Epub 2014 Mar 24.

PMID:
24571445
7.

The AusD Study: a population-based study of the determinants of serum 25-hydroxyvitamin D concentration across a broad latitude range.

Brodie AM, Lucas RM, Harrison SL, van der Mei IA, Armstrong B, Kricker A, Mason RS, McMichael AJ, Nowak M, Whiteman DC, Kimlin MG.

Am J Epidemiol. 2013 May 1;177(9):894-903. doi: 10.1093/aje/kws322. Epub 2013 Mar 22.

PMID:
23524036
8.

Zinc, cadmium, and mercury complexes of a pyridyloxy-substituted cyclotriphosphazene: syntheses, structures, and fluxional behavior.

Ainscough EW, Brodie AM, Edwards PJ, Jameson GB, Otter CA, Kirk S.

Inorg Chem. 2012 Oct 15;51(20):10884-92. doi: 10.1021/ic3013574. Epub 2012 Oct 1.

PMID:
23025919
9.

Toward an iron(II) spin-crossover grafted phosphazene polymer.

Davidson RJ, Ainscough EW, Brodie AM, Jameson GB, Waterland MR, Allcock HR, Hindenlang MD, Moubaraki B, Murray KS, Gordon KC, Horvath R, Jameson GN.

Inorg Chem. 2012 Aug 6;51(15):8307-16. doi: 10.1021/ic300853f. Epub 2012 Jul 10.

PMID:
22780572
10.

Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.

Yang X, Guo Z, Sun F, Li W, Alfano A, Shimelis H, Chen M, Brodie AM, Chen H, Xiao Z, Veenstra TD, Qiu Y.

J Biol Chem. 2011 Oct 14;286(41):36152-60. doi: 10.1074/jbc.M111.265124. Epub 2011 Aug 30.

11.

Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.

Bruno RD, Vasaitis TS, Gediya LK, Purushottamachar P, Godbole AM, Ates-Alagoz Z, Brodie AM, Njar VC.

Steroids. 2011 Nov;76(12):1268-79. doi: 10.1016/j.steroids.2011.06.002. Epub 2011 Jun 24.

12.

Aromatase inhibitors and xenograft studies.

Chumsri S, Sabnis GJ, Howes T, Brodie AM.

Steroids. 2011 Jul;76(8):730-5. doi: 10.1016/j.steroids.2011.02.033. Epub 2011 Mar 21.

13.

Extending aromatase inhibitor sensitivity in hormone resistant breast cancer.

Brodie AM, Chumsri S, Sukumar S, Sabnis GJ.

Horm Mol Biol Clin Investig. 2011 Mar 1;5(2):97-103. doi: 10.1515/HMBCI.2011.010.

PMID:
25961245
14.

Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.

Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM.

Cancer Res. 2011 Mar 1;71(5):1893-903. doi: 10.1158/0008-5472.CAN-10-2458. Epub 2011 Jan 18.

15.
16.

Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.

Tilghman SL, Sabnis G, Brodie AM.

Horm Mol Biol Clin Investig. 2010 Dec 1;3(1):357-66. doi: 10.1515/HMBCI.2010.042.

PMID:
25961207
17.

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.

Schayowitz A, Sabnis G, Goloubeva O, Njar VC, Brodie AM.

Br J Cancer. 2010 Sep 28;103(7):1001-7. doi: 10.1038/sj.bjc.6605882. Epub 2010 Sep 14.

18.

Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer.

Yao Y, Brodie AM, Davidson NE, Kensler TW, Zhou Q.

Breast Cancer Res Treat. 2010 Nov;124(2):585-91. doi: 10.1007/s10549-010-1023-8. Epub 2010 Jul 10.

19.

Excited states of Ru(II) and Re(I) bipyridyl complexes attached to cyclotriphosphazenes: a synthetic, spectroscopic, and computational study.

Horvath R, Otter CA, Gordon KC, Brodie AM, Ainscough EW.

Inorg Chem. 2010 May 3;49(9):4073-83. doi: 10.1021/ic902171j.

PMID:
20377232
20.

Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells.

Burks SR, Macedo LF, Barth ED, Tkaczuk KH, Martin SS, Rosen GM, Halpern HJ, Brodie AM, Kao JP.

Breast Cancer Res Treat. 2010 Nov;124(1):121-31. doi: 10.1007/s10549-009-0715-4. Epub 2010 Jan 12.

21.

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.

Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y.

Cancer Res. 2009 Mar 15;69(6):2305-13. doi: 10.1158/0008-5472.CAN-08-3795. Epub 2009 Feb 24.

22.

Metal-metal communication in copper(II) complexes of cyclotetraphosphazene ligands.

Ainscough EW, Brodie AM, Davidson RJ, Moubaraki B, Murray KS, Otter CA, Waterland MR.

Inorg Chem. 2008 Oct 20;47(20):9182-92. doi: 10.1021/ic8008706. Epub 2008 Sep 26.

PMID:
18817378
23.

17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.

Bruno RD, Gover TD, Burger AM, Brodie AM, Njar VC.

Mol Cancer Ther. 2008 Sep;7(9):2828-36. doi: 10.1158/1535-7163.MCT-08-0336.

24.

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM.

Mol Cancer Ther. 2008 Aug;7(8):2348-57. doi: 10.1158/1535-7163.MCT-08-0230.

25.

Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?

Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE.

Oncologist. 2008 Aug;13(8):829-37. doi: 10.1634/theoncologist.2008-0055. Epub 2008 Aug 11. Review.

26.

Stopping treatment can reverse acquired resistance to letrozole.

Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, Brodie AM.

Cancer Res. 2008 Jun 15;68(12):4518-24. doi: 10.1158/0008-5472.CAN-07-5999.

27.

Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro.

Schayowitz A, Sabnis G, Njar VC, Brodie AM.

Mol Cancer Ther. 2008 Jan;7(1):121-32. doi: 10.1158/1535-7163.MCT-07-0581.

28.

Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.

Come SE, Buzdar AU, Ingle JN, Johnston SRD, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE.

Cancer. 2008 Feb 1;112(3 Suppl):673-678. doi: 10.1002/cncr.23194.

29.

Conformationally rigid chelate rings in metal complexes of pyridyloxy-substituted 2,2'-dioxybiphenyl-cyclotetra- and cyclotriphosphazene platforms.

Ainscough EW, Brodie AM, Derwahl A, Kirk S, Otter CA.

Inorg Chem. 2007 Nov 12;46(23):9841-52. Epub 2007 Oct 20.

PMID:
17949082
30.

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.

Patel JB, Mehta J, Belosay A, Sabnis G, Khandelwal A, Brodie AM, Soprano DR, Njar VC.

Br J Cancer. 2007 Apr 23;96(8):1204-15. Epub 2007 Mar 27.

31.

Conformational flexibility in 2,2'-Dioxybiphenyl-chloro-cyclotetraphosphazenes and its relevance to polyphosphazene analogues.

Ainscough EW, Brodie AM, Chaplin AB, Derwahl A, Harrison JA, Otter CA.

Inorg Chem. 2007 Apr 2;46(7):2575-83. Epub 2007 Mar 3.

PMID:
17335275
32.
33.
34.

Regulation of androgen receptor activity by tyrosine phosphorylation.

Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, Njar VC, Brodie AM, Yu LR, Veenstra TD, Chen H, Qiu Y.

Cancer Cell. 2006 Oct;10(4):309-19. Erratum in: Cancer Cell. 2007 Jan;11(1):97.

35.

The effect of tamoxifen on the pharmacokinetics of letrozole in female rats.

Tao X, Brodie AM, Nnane IP.

Biopharm Drug Dispos. 2006 Oct;27(7):335-44.

PMID:
16912967
36.

A versatile synthesis of 17-heteroaryl androstenes via palladium-mediated Suzuki cross-coupling with heteroaryl boronic acids.

Chao J, Ling Y, Liu X, Luo X, Brodie AM.

Steroids. 2006 Jul;71(7):585-90. Epub 2006 Mar 29.

PMID:
16566953
37.

Gold(I) and platinum(II) complexes with a new diphosphine ligand based on the cyclotriphosphazene platform.

Ainscough EW, Brodie AM, Chaplin AB, O'Connor JM, Otter CA.

Dalton Trans. 2006 Mar 14;(10):1264-6. Epub 2005 Dec 23.

PMID:
16505903
39.

Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.

Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, Hussain A.

Clin Cancer Res. 2006 Jan 1;12(1):169-74.

40.

Polymer building blocks: self-assembly of silver(I) cyclotriphosphazene cationic columns.

Ainscough EW, Brodie AM, Depree CV, Jameson GB, Otter CA.

Inorg Chem. 2005 Oct 17;44(21):7325-7.

PMID:
16212358
41.

Copper(II) chloride complexes with multimodal ligands based on the cyclotriphosphazene platform.

Ainscough EW, Brodie AM, Depree CV, Moubaraki B, Murray KS, Otter CA.

Dalton Trans. 2005 Oct 21;(20):3337-43. Epub 2005 Aug 26.

PMID:
16193152
42.

Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.

Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM.

Cancer Res. 2005 Jun 15;65(12):5439-44.

43.

Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.

Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM.

Cancer Res. 2005 Jun 15;65(12):5380-9.

44.

Structural and spectroscopic studies on mercury(II) tribenzylphosphine complexes.

Bowmaker GA, Assadollahzadeh B, Brodie AM, Ainscough EW, Freeman GH, Jameson GB.

Dalton Trans. 2005 May 5;(9):1602-12. Epub 2005 Mar 31.

PMID:
15852109
46.

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D Jr, Farquhar R, Guo Z, Qiu Y, Brodie AM.

J Med Chem. 2005 Apr 21;48(8):2972-84.

PMID:
15828836
47.

Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.

Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristensen VN, Lønning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):861s-4s. No abstract available.

48.

Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.

Patel JB, Huynh CK, Handratta VD, Gediya LK, Brodie AM, Goloubeva OG, Clement OO, Nanne IP, Soprano DR, Njar VC.

J Med Chem. 2004 Dec 30;47(27):6716-29.

PMID:
15615521
49.

Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.

Handratta VD, Jelovac D, Long BJ, Kataria R, Nnane IP, Njar VC, Brodie AM.

J Steroid Biochem Mol Biol. 2004 Oct;92(3):155-65.

PMID:
15555909
50.

Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.

Jelovac D, Macedo L, Handratta V, Long BJ, Goloubeva OG, Ingle JN, Brodie AM.

Clin Cancer Res. 2004 Nov 1;10(21):7375-81.

Supplemental Content

Loading ...
Support Center